Editorial: Statins sentence thyroid cancer cells to death rho

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 7, 2003, Pages 3019-3020

  Robbins, Richard J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESOL; FARNESYL TRANS TRANSFERASE; GERANYLGERANIOL; GERANYLGERANYLTRANSFERASE; GERANYLTRANSFERASE; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RHO FACTOR; STATINE DERIVATIVE; THYROGLOBULIN; UNCLASSIFIED DRUG; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ANAPLASTIC CARCINOMA; ANAPLASTIC THYROID CARCINOMA; CANCER CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; DRUG ACTIVITY; DRUG MECHANISM; EDITORIAL; HUMAN; MICROVILLUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; SECRETORY GRANULE; THYROID CANCER; THYROID CARCINOMA; CARCINOMA; DRUG EFFECT; NOTE; PATHOLOGY; PHYSIOLOGY; THYROID TUMOR;

CARCINOMA; CELL DEATH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; RHO GTP-BINDING PROTEINS; THYROID NEOPLASMS;

EID: 0041764509     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030827     Document Type: Editorial

References (22)

1. Ain KB 2000 Management of undifferentiated thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab 14:615-629
2. Giuffrida D, Gharib H 2000 Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 11:1083-1089
3. Ain KB, Egorin MJ, DeSimone PA 2000 Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587-594
4. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP 2001 Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 22:631-656
5. Wiseman SM, Loree TR, Hicks Jr WL, Rigual NR, Winston JS, Tan D, Anderson GR, Stoler DL 2003 Anaplastic thyroid cancer evolved from papillary carcinoma: demonstration of anaplastic transformation by means of the inter-simple sequence repeat polymerase chain reaction. Arch Otolaryngol Head Neck Surg 129:96-100
6. Vella V, Zhu J, Frasca F, Li CY, Vigneri P, Vigneri R, Wang JY 2003 Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function. J Biol Chem, in press
7. Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, Mitsutake N, Kanda S, Kurebayashi J, Yamashita S 2003 The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88:1889-1896
8. Urbich C, Dernbach E, Zeiher AM, Dimmeler S 2002 Double-edged role of statins in angiogenesis signaling. Circ Res 90:737-744
9. Wang C-Y, Zhong W-B, Chang T-C, Lai S-M, Tsai Y-F 2003 Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88:3021-3026
10. Aznar S, Lacal JC 2001 Rho signals to cell growth and apoptosis. Cancer Lett 165:1-10
11. Sahai E, Marshall CJ 2002 RHO-GTPases and cancer. Nat Rev Cancer 2:133-142
12. Frame MC, Brunton VG 2002 Advances in Rho-dependent actin regulation and oncogenic transformation. Curr Opin Genet Dev 12:36-43
13. Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL 2002 Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 87:1814-1818
14. Pervaiz S, Cao J, Chao OS, Chin YY, Clement MV 2001 Activation of the RacGTPase inhibits apoptosis in human tumor cells. Oncogene 20:6263-6268
15. Bifulco M, Laezza C, Aloj SM, Garbi C 1993 Mevalonate controls cytoskeleton organization and cell morphology in thyroid epithelial cells. J Cell Physiol 155:340-348
16. Vitale M, Di Matola T, Rossi G, Laezza C, Fenzi G, Bifulco M 1999 Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent CrmA-sensitive, and caspase-3-like protease-dependent mechanism. Endocrinology 140:698-704
17. Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, Harlan JM 2002 Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 277:15309-15316
18. Feleszko W, Mlynarczuk I, Olszewska D, Jalili A, Grzela T, Lasek W, Hoser G, Korczak-Kowalska G, Jakobisiak M 2002 Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer 100:111-118
19. Swamy MV, Cooma I, Reddy BS, Rao CV 2002 Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int J Oncol 20:753-759
20. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, Kamel-Reid S 2002 Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 4:337-346
21. van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC 2002 The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16:1362-1371
22. Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE 2003 Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 24:453-459